CDC7 · Western blot design guide

CDC7 Western Blot Planning Guide

Plan a CDC7 Western blot around the catalog-observed 63.9 kDa band, image-backed A01190-3 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for CDC7 (CDC7): expected band 63.9 kDa, antibody A01190-3, and guide-derived SDS-PAGE protocol steps
CDC7 Western blot protocol sheet — expected band 63.9 kDa, antibody A01190-3, controls and PMC citations. Open the full CDC7 WB guide →

CDC7 Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 63.9 kDa
Observed band Not reported — verify product WB image
Gel 12-15%
Positive control ⓘ Skin
Negative control ⓘ Heart muscle
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 63.9 kDa
ⓘ Localization Nucleus
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human
Section 1

Real Curated CDC7 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateAppendix
Gel %12-15%
Load20-30 µg total protein per lane
TransferSemi-dry, standard transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryA01190-3 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected CDC7 Western Blot Band Size?

Use the product-observed 63.9 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
63.9 kDaMatches the authoritative product WB observation.
63.9 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected CDC7 appearancePlan around 63.9 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band63.9 kDa; use this as the primary experimental expectation.
Calculated mass63.9 kDa from UniProt O00311; retain as context.
Gel selection12-15%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with A01190-3.
Why is my band missing or off?
SituationLikely causeNext action
63.9 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for CDC7 Western blot

🧪Use Skin as the first positive-control candidate and Heart muscle as the HPA Not detected negative candidate.
Positive control: Skin (High)
Negative control: Heart muscle (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for CDC7

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Skin Reported tissue cells High Protein (HPA) HPA →
Stomach Reported tissue cells High Protein (HPA) HPA →
Appendix Reported tissue cells High Protein (HPA) HPA →
Lymph node Reported tissue cells High Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Heart muscle Reported tissue cells Not detected Protein (HPA) HPA →
Hippocampus Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced CDC7 Western Blot Tips

Deeper troubleshooting and optimisation questions for CDC7, answered from its protein features.

Which band should guide the blot?
Use 63.9 kDa, the observation attached to the authoritative A01190-3 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 63.9 kDa expectation.
Which positive control should I start with?
Start with Skin, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Heart muscle as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for CDC7 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A01190-3 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

CDC7 Western Blot Reagents

Human-reactive CDC7 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for CDC7 using A01190-3; observed band 63.9 kDa
Anti-CDC7 Antibody Picoband®
Cat # A01190-3

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt O00311
  2. Human Protein Atlas — CDC7
  3. A01190-3 product record
  4. PMC4225225 — MiR-630 inhibits proliferation by targeting CDC7 kinase, but maintains the apoptotic balance by targeting multiple modulators in human lung cancer A549 cells (Cell death & disease, 2014)
  5. PMC4951304 — Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint (Oncotarget, 2016)